Tigecycline's Unique Spectrum
Tigecycline, a glycylcycline antibiotic, covers multidrug-resistant (MDR) Gram-positive bacteria like MRSA and VRE, most Gram-negative pathogens including Acinetobacter baumannii and extended-spectrum beta-lactamase (ESBL) producers, and anaerobes. It lacks activity against Pseudomonas aeruginosa and Proteus species due to efflux pumps.[1]
How It Differs from Tetracycline Generics
Tigecycline overcomes common tetracycline resistance mechanisms (e.g., ribosomal protection, efflux) that limit generics like doxycycline or minocycline. Generics retain activity against susceptible Gram-positives (e.g., some streptococci) and limited Gram-negatives (e.g., H. influenzae), but fail against many MDR strains where tigecycline succeeds. Generics have broader coverage against some atypicals like Chlamydia, while tigecycline does not.[1][2]
| Pathogen Group | Tigecycline | Tetracycline Generics (e.g., Doxycycline) |
|----------------|-------------|------------------------------------------|
| MRSA/VRE | Strong | Weak/None (resistance common) |
| ESBL Gram-negatives | Strong | Weak/None |
| Acinetobacter | Strong | None |
| Pseudomonas | None | None |
| Anaerobes | Strong | Moderate |
| Atypicals (e.g., Chlamydia) | None | Strong |
Comparison to Other Generic Antibiotics
Against generic beta-lactams (e.g., piperacillin-tazobactam), tigecycline covers more MDR Gram-negatives but misses Pseudomonas, which those generics hit. Versus generic aminoglycosides (e.g., gentamicin), tigecycline avoids nephrotoxicity and covers anaerobes better, but gentamicin reaches Pseudomonas.[1][3]
Clinical Implications of Spectrum Gaps
Tigecycline's MIC creep in Enterobacterales and poor lung penetration limit it to skin, intra-abdominal, and complicated infections. Generics like doxycycline suit outpatient respiratory or STI cases due to oral dosing and atypical coverage. Resistance emergence in Klebsiella and E. coli reduces tigecycline's edge over generics in some settings.[2][3]
Availability and Patent Status
Tigecycline (Tygacil) lost exclusivity in the US in 2020-2021; generics from multiple manufacturers (e.g., Mylan, Sandoz) match the brand's spectrum exactly, as they are AB-rated equivalents.[4] No spectrum differences exist between branded and generic tigecycline.
[1] https://www.ncbi.nlm.nih.gov/books/NBK548679/
[2] https://academic.oup.com/jac/article/73/6/1401/4954045
[3] https://www.idsociety.org/practice-guideline/amr-guidance/
[4] https://www.drugpatentwatch.com/p/tradename/TYGACIL